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Abstract
Antisense oligonucleotides (ASO) are single-stranded deoxyribonucleic acids that bind to
mRNA to inhibit the synthesis of proteins that have been associated with the central mechanisms
of disease development. Due to their gene silencing capabilities, the potential for ASOs as
therapeutic agents is wide, but many toxicological challenges such as poor membrane
permeability, low solubility, and rapid degradation by exonucleases must be overcome before
ASO medications can be reliably utilized. In order to negate these challenges, the natural sugarphosphate backbone of ASO’s, which is responsible for its rapid degradation, will be replaced by
one that is hydrolytically stable. To do so, synthetic oligonucleotide analogues that lack the
traditional ribose-phosphate backbone are being developed and will be studied to assess their
stability and ability to suppress gene expression.

Introduction
The availability of novel drugs in genetic medicine has the potential to treat
neurodegenerative disorders, such as Alzheimer’s and Parkinson’s disease, and other rare genetic
conditions for which there is no current therapy. The majority of approved drugs target the end
product of gene translation: the proteins involved in the central mechanisms of disease
development. However, as of recent, research has shifted to focus on biologically active
molecules that target RNA or DNA as potential therapeutic agents. Among these molecules of
interest, a new class of synthetic single stranded molecules of nucleic acids, antisense
oligonucleotides (ASOs), have demonstrated promising experimental results due to their ability
to target hnRNAs or mRNAs, interfere with mRNA splicing, and arrest gene translation, thus
reducing or inhibiting target protein expression.1
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The ability of ASOs to promote a highly specific reduction in the amount of a mRNA
makes the clinical application of antisense technologies highly attractive. However, natural
ASOs are inherently unstable due to their phosphodiester-sugar backbones, which quickly get
degraded in vivo via exonucleases into monomers that have deleterious non-specific binding
properties.2 As a result, modifying the oligonucleotide backbone to increase nuclease resistance
has become an important goal in medicinal chemistry research. A variety of modification
strategies have been reported, such as altering the phosphodiester moiety (for example,
phosphoramidate, methylphosphonate, and phosphorodiamidate morpholino), changing the
backbone linkage altogether (as in peptide nucleic acids), and eliminating the target of nucleases,
the deoxyribose ribose ring (simplified glycol nucleic acid oligonucleotides).3, 4, 5
Despite containing modified backbones, current ASOs still face many challenges that
include, but are not limited to, poor membrane permeability, poor potency, non-specific effects,
rapid degradation by exonucleases, and short-shelf life, making them unacceptable as therapeutic
drugs.3 To address these issues, a novel synthetic strategy that replaces the traditional ASO sugar
backbone with an oligomer derived from seven-membered carbon rings has been developed
(Figure 1).
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Figure 1. Seven-membered cyclic monomers containing guanine, adenine, cytosine,
thymine, and uracil, respectively
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Currently, our research aims to synthesize all desirable cyclic monomers. Once the
individual bases are made, nuclease-resistant ASOs will be synthesized in one-step from suitable
monomers using a DNA templated ring opening metathesis polymerization (TROMP, Figure 2).
Following TROMP, heat will be used to break the hydrogen bonds holding the two strands
together; the specific product ASO analogue will be extracted and the DNA template will be
recycled and reused. Further experiments in vitro will be performed to determine and assess the
stability, binding specificity, and gene suppression effectiveness of the ASO analog. The aim is
to synthesize stable ASO analogs, making the application of oligonucleotides more efficient as
systemic drugs.
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Figure 2. Synthesis of ASO analog via templated ring opening metathesis polymerization

Experimental
Reactions were carried out under dry N2 gas. Unless stated otherwise, solvents and
reagents were used as obtained from commercial suppliers. Dimethylformamide (DMF),
tetrahydrofuran (THF), toluene, and ether are dried and purified via a SPPS system. NMR
analyses were conducted on either Bruker Advance DPX-300 or Bruker Advance DRX-400.
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2

Compound 3T (base = thymine). Sodium hydride (0.305 g, 12.71 mmol), DMF (20 mL), and
the base thymine (1.07 equivalent of 2) were placed in a two-necked flask and stirred under N2
gas for 2 h. Allyl glycidyl ether 2 (2.30 mL, 28.8 mmol) dissolved in DMF (60 mL) was then
added into reaction mixture; the reaction was brought to 110-120 °C and was heated at reflux for
16 h. The DMF was removed via short-path distillation in vacuo. The product was extracted
from the remaining solid with ethyl acetate, which was then removed using a rotary evaporator.
The prodcut was purified via column chromatography (7:3 of hexanes: ethyl acetate); total yield
was 64%. 1H NMR (400 MHz, CDCl3) d 7.13 (s, 1H); 5.88 (ddt, J = 17.2, 10.4, 5.7 Hz, 1H);
5.28 (ddd, J = 17.2, 1.8,1.5 Hz, 1H); 5.22 (ddd, J = 10.4, 1.8, 1.2 Hz, 1H); 4.08 (m, 1H); 4.02
(apparent dt, J = 5.7, 1.3 Hz, 2H); 3.97 (dd, J = 14.3, 3.2, 1H); 3.69 (dd, J = 9.7, 6.0 Hz, 1H);
3.52 (dd, J = 9.7, 4.4 Hz, 1H); 3.43 (dd, J = 9.7, 6.0 Hz, 1H); 1.89 (s, 1H).

Ag2O,
Br

OH

O

O
3

O

base

4

base

Compound 4T. Compound 3T, 3-Bromo-2-methylpropene, Ag2O, and dry DMF were
placed in a round-bottomed flask and stirred under N2 at room temperature for 16 h. The DMF was
removed via short-path vacuum distillation, and the crude product was purified via column
chromatography (1:1:0.1 of ethyl acetate, hexanes, and triethylamine).
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Compound 7. A flask containing NaH (11 g, 275 mmol) and THF (500 mL) was placed in an ice
bath; and allyl alcohol (17 mL, 250 mmol) was added dropwise via syringe to the mixture. The
ice bath was then removed, and the solution was stirred under N2 gas for 2 h. Afterwards, allyl
glycidyl ether was added to the reaction mixture. The mixture was brought to reflux for 24 h.
After cooling to room temperature, methylene chloride (500 mL) was added to the solution. This
mixture was washed with water and the organic extracts were dried (MgSO4), and the solvent
was removed via rotary evaporation. The crude product was purified via vacuum fractional
distillation (1 mmHg). Four fractions were collected at different temperature ranges: 0-80° C for
fraction I, around 80° C for fraction II, 83-115° C for fraction III, and around 115° C for fraction
IV. Product (16.573 g, 39%) was collected from fraction III and IV. 1H NMR (400 MHz, CDCl3)
d 5.87 (ddt, J = 17.4, 10.4, 5.9 Hz, 2H); 5.26 (dd, J = 17.6, 1.0, 2H); 5.19 (br d, J = 10.4 Hz, 2H);
3.99 (d, J = 5.7 H, 4H); 3.92 (m, 1H); 3.51 (dd, J = 10.7, 4.1, 2H); 3.46 (dd, J = 10.7, 6.6 Hz,
2H).
OH
OH
O

ring closing
metathesis

O

O

O

7
8

Compound 8. A ring-closing metathesis (RCM) was attempted to convert Compound 7
into 8 under a variety of conditions (Table 1 in Results and Discussion).
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Diethyl-2,2-di-(3-butenyl)malonate (9). Sodium hydride (5.025g, 0.1256 mol) and dry
DMF (50 mL) were added into a 250 mL round-bottomed flask, which was placed under N2, and
cooled in an ice bath. Diethylmalonate (16.90 mL, 0.1113 mol) was added dropwise via syringe,
and the reaction was stirred at room temperature for 30 min. The mixture was cooled in an ice
bath and bromobutene (11.3 mL, 111.3 mmol) was added dropwise via syringe. The mixture
continued to stir under N2 at room temperature for 18 h, after which it was cooled in an ice bath.
Another portion of sodium hydride (5.138g, 128.5 mmol) was added in four parts over 45 min.
The mixture stirred under N2 while warming from 0 °C to room temperature for 16 h. The
reaction mixture was then stirred for 72 hours. Sodium hydride (2.096g, 84 mmol) was added
once more, and the mixture was stirred at room temperature for an hour. Bromobutene (4.40 mL,
40.7 mmol) was also added dropwise to the mixture once again; the reaction was allowed to
proceed for 24 h at room temperature. Diethyl ether was then added to the mixture, which was
then washed with water 3 times with water. The ether layer was dried over MgSO4, filtered, and
solvent was removed via rotary evaporation, leaving an oil that was filtered through a silica plus
to yield 26.372 g (88%) of the desired product. 1H NMR (400 MHz, CDCl3) d 5.80 (ddt, J =17.0,
10.3, 7.2 Hz, 2H); 5.03 (ddt, J = 17.0, 406, 1.9 Hz, 2H); 5.00 (ddt, J = 10.2, 1.9, 1.3 Hz, 2H);
4.20 (quart, J, 7.2, 4H); 2.08 (apparent t quart, J = 7.2, 1.2 Hz, 4H); 1.90 (m, 4H); 1.26 (t, J = 7.1
Hz, 6H).
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Diethyl 1-cycloheptenedicarboxylate (10). A 2-liter round-bottomed flask containing
0.75 L of degassed dichloromethane, diethyl-2,2-di-(3-butenyl)malonate (9, 1.015 g, 3.785
mmol), and G1 catalyst (0.150g, 0.182 mmol) was stirred for 5 d. The solvent was then removed,
and the crude product was dissolved in hexanes (10 mL) and filtered through silica, which was
then washed with 10% ethyl acetate/hexanes. After removal of the solvents via rotary
evaporation, a tan oil was obtained (0.906 g, 99.6% yield). 1H NMR (400 MHz, CDCl3) d 5.67
(br s, 2H); 4.21 (quart, J = 6.9 Hz, 4H); 2.25 (m, 8H); 1.27 (t, J = 7.0 Hz, 6H).

EtO2C

CO2Et

1. NaOH, EtOH
2. decalin, heat

CO2H

62%
11
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4-Cycloheptene-1-Carboxylic Acid (11). Compound 10 (1.644 g, 6.85 mmol), NaOH
(1.436g, 35.9mmol), ethanol (5 mL), water (10 mL), and THF (3 mL) were combined in a roundbottomed flask fitted with a condenser and stir bar. The reaction was brought to reflux under N2
and kept there for 48 h. Upon cooling to room temperature, water (30 mL) and concentrated HCl
were added to the reaction until the pH reached 1-2. The mixture was extracted with ether, dried
with MgSO4, and the solvent removed, leaving a white powder (1.260 g, 100%). A portion of the
hydrolyzed product (0.213 g, 1.16 mmol) and DMAP (2.5 g, 21 mmol) were suspended in
decalin (7.5 mL) and brought to reflux under N2 for 28 h. The mixture was cooled and suspended
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in hexane. A silica column was run, first using hexanes to pull of decalin, then ethyl acetate to
elute compound 11 (0.101 g, 62%). 1H NMR (400 MHz, CDCl3) d 5.80 (m, 2H); 2.64 (tt, J = 9,7,
4.1 Hz, 1H); 2.33 (m, 2H); 2.13 (m, 2H); 2.03 (m, 2H); 1.69 (m, 2H). Lit:7 δ 5.78 (t, 2H,
HC=CH), 2.6 (m, 1H, H2C-CH-CH2), 2.4 (m, 4H, HC-CH2-CH2), 2.2 (m, 4H, HC=CH-CH2 CH2).
CO2H

OH

1. LiAlH4
2. H3O+
90%

11

12

5-hydroxymethylcycloheptene (12). 4-Cycloheptene-1-carboxylic acid (1.020 g, 6.788
mmol) and diethyl ether (35 mL) were placed in a round bottom flask equipped with a stir bar,
condenser, and septum. Lithium aluminum hydride (LAH, 3.0 mL, 7.2 mmol) was added slowly
over the course of 45 minutes with the reaction producing rapid evolution of H2 gas. The flask
was swirled intermittently during this addition. Following LAH, the mixture was brought to
reflux under N2 gas for 3 hours then cooled to 0°C. The cold reaction mixture was stirred
vigorously and quenched by the dropwise addition of water (6 mL), 15% aqueous sodium
chloride (6 mL), and water (2.3 mL). The mixture was filtered and 1/5 of the solids was extracted
by THF with a soxhlet apparatus. The THF and filtrate were treated with 7% NaOH (6 mL) and
H2O (2 x 6 mL), dried with MgSO4 and filtered. The solvent was removed via rotavap to give a
pale yellow liquid (0.896 g, 90%). 1H NMR (400 MHz, CDCl3) δ 5.78 (t, 2H, HC=CH), 3.47 (d,
2H, CH2-OH), 2.1/2.08 (m, 4H, HC-CH2-CH2), 1.77 (m, 1H, CH2-CH-CH2), 1.57 (s, 1H, CH2OH).
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Compound 1A. 5-hydroxymethylcycloheptene (320 mg, 2.36 mmol) reacted with
adenine (401 mg, 2.97 mmol) and triphenylphosphine (PPh3: 760 mg, 2.89 mmol) in a roundbottomed flask. Under N2 gas, diethyl azodicarboxylate (DEAD: 0.45 mL, 2.85 mmol) was added
dropwise to the reaction mixture via syringe. The reaction was allowed to proceed for 5 d, after
which the solvent was removed via rotary evaporation. Dichloromethane (50 mL) was added, and
this solution was loaded onto a column (SiO2 and CH2Cl2), from which the product was eluted
with 2% MeOH/CH2Cl2 (200 mL), followed by 5% MeOH/CH2Cl2 (150 mL). Removal of the
chromatography solvent gave the desired product (0.170g, 27%). 1H NMR (300 MHz, CDCl3) d
5.8.40 (s, 1H); 7.78 (s, 1H); 5.81 (m, 2H); 5.64 (br s, 2H); 4.09 (d, J = 7.4 2H); 1.74 (m, 2H); 1.19
(m, 2H). 13C NMR (100 Mhz, CDCl3) d 155.4, 153.0, 150.4, 141.0, 134.9, 119.6, 49.9, 42.4, 30.4,
26.3.

O

Me2NH, CaCl2,
Et2O

NMe2

45%
14

N,N-Dimethyl-1-cylclopenten-1-amine (14). This reaction was done twice, and then
combined for the distillation Dimethylamine hydrochloride (40.095 g, 491.66 mmol) was
dissolved in a minimum amount of water and added dropwise to a three-necked flask containing
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NaOH (40.05g, 1.001 mol). The gaseous product of this addition, dimethylamine, passed through
a drying tube containing NaOH before it was condensed and collected in a two-necked flask
submerged in a liquid nitrogen/ethyl acetate bath. A slight vacuum was employed to pull off the
remaining amine in the reaction flask. The liquid dimethylamine was then added to a round
bottom flask, containing CaCl2 (22.98 g, 207.0 mmol) and dry ether (200 mL). Cyclopentanone
(8.0 mL, 90.3 mmol) was also added via syringe. The solution was kept under N2 at room
temperature for 3 d. Afterwards, the solution was filtered and CaCl2 was washed with dry ether
(200 mL).
The second reaction was conducted the same way, using 280.180 g (3.436 mol) of
dimethyamine hydrochloride, 280.230 g (7.006 mol) of NaOH, 160.860 g (1.449 mol) of CaCl2,
56.0 mL (0.632 mol) of cyclopentanone, and 1.0 L of dry ether.
The two reaction mixtures were combined and the ether was removed via rotary
evaporation and the remaining solution was distilled under vacuum via vigreux column (bp 8081 oC at 105 mmHg) to give the enamine (35.860 g, 45%). 1H NMR (400 MHz, CDCl3) δ 4.25
(s, 1H, C=CH-CH2), 2.6 (s, 6H, (CH3)2-N), 2.42 (m, 2H, (N-C)-CH2-CH2), 2.39 (m, 2H,
(C=CH)-CH2-CH2), 1.9 (m, 2H, CH2-CH2-CH2).

KHSO4, K2SO4, heat

OH
HO

OH

O

28%

Acrolein. The apparatus for acrolein synthesis: a 500 mL three-necked flask (F1) with
pressure equalizing addition funnel, a 100 mL three-necked flask (F2), and a second 100 mL
three-necked flask (F3) submerged in ice (Figure 3). Potassium sulfate (20.001 g, 114.8 mmol),
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fused potassium bisulfate (102.58, 753.4 mmol) and 30.000 g of glycerol were added to F1 and
heated to 190-200°C, thus causing the reaction to foam/froth. As F1 was being heated to 190°C,

Figure 3. Apparatus setup for acrolein synthesis
F2 was heated to 100-110°C. After the reaction in F1 proceeded for an h or when the frothing
died down , glycerol (30.309 g) was added dropwise to F1 from the pressure equalizing addition
funnel. The reaction in F1 continued to run for 4 h before the apparatus was disconnected from
F2. F2 was then heated for another 1-2 h at 190-200 oC until no more liquid was collecting in F3,
which contained about 1 g of hydroquinone and which had been cooled in an ice bath. At this
point, F3 was heated to distill the acrolein into the final flask, which also contained about 1 g of
hydroquinone as a stabilizer before being disassembled and storage of acrolein occurred. The
product distilled at 53 to 55 oC and was found to weigh 10.202 g (28%). 1H NMR (400 MHz,
CDCl3) δ 9.55(s, 1H, O=CH), 6.5 (t, 1H, H2C=CH-(O=CH)), 6.4 (m, 2H, H2C=CH).
NMe2

O

Me2N

O

1. MeI, MeCN
2. NaOH

CO2H

32% (2 steps)
14

15

11

14

4-Cycloheptene-1-Carboxylic Acid (11). To a round-bottomed flask equipped with a stir bar,
placed under nitrogen, and cooled in an ice bath, N,N-Dimethyl-1-cylclopenten-1-amine (16.600
g, 149.4 mmol) was added. Following the addition of the enamine, acrolein (10.0 mL, 149.7
mmol) was added dropwise over the course of an h. Upon warming to room temperature, the
reaction was stirred for 3 h, then anhydrous acetonitrile (37 mL) was added to the mixture. The
reaction was then cooled using an ice bath, and iodomethane (9.5 mL, 152.6 mmol) was added
dropwise over the course of 90 min. The resulting solution was then frozen overnight and
allowed to thaw out in the morning. After thawing/stirring for 2 h, an aqueous solution of 20%
NaOH (147 mL) was added and the resulting mixture was heated to reflux for 19 h. The brown
mixture was cooled, and the aqueous layer was extracted with dichloromethane (73 mL). The
aqueous layer was acidified with concentrated HCl and a yellow-white precipitate formed. The
precipitate was filtered out and the filtrate was again treated with HCl (3 times), allowing more
precipitate to form, giving the desired product (7.165g, 32%). 1H NMR (400 MHz, CDCl3) d
5.80 (m, 2H); 2.64 (tt, J = 9,7, 4.1 Hz, 1H); 2.33 (m, 2H); 2.13 (m, 2H); 2.03 (m, 2H); 1.69 (m,
2H). Lit:7 δ 5.78 (t, 2H, HC=CH), 2.6 (m, 1H, H2C-CH-CH2), 2.4 (m, 4H, HC-CH2-CH2), 2.2
(m, 4H, HC=CH-CH2-CH2).
OH

OMs
MsCl, DIPEA, CH2Cl2
95%
16
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Mesylate 16. The alcohol 12 (0.105 g, 76.2 mmol) and diisopropylethylamine (DIPEA, 0.216 g,
159 mmol) were added to a 20 mL round-bottomed flask equipped with a stir bar. Dichloromethane (5.0 mL) was added, followed by mesyl chloride (0.061 mL, 78.8 mmol). The Flask
was capped with a septum and was placed under N2. The mixture was stirred for 16 h, after
15

which CH2Cl2 (15 mL) was added. This solution was extracted with saturated aqueous NaHCO3,
and the aqueous layer was separated and extracted with CH2Cl2 (3 x 10 mL). The combined
organic layers were dried over sodium sulfate, filtered, and concentrated in vacuo to give 0.138 g
(95%) of the product. 1H NMR (400 MHz, CDCl3) d 5.79 (m, 2H); 4.05 (d, J = 6.6 Hz, 2H);
2.30-2.21 (m, 2H); 2.14-2.03 (m, 2H); 2.04-1.95 (m, 2H); 1.87-1.79 (m, 2H); 1.27-1.17 (m, 2H).
O
OMs

NH
thymine, K2CO3,
NaI, DMF

N

O

25%
16
1T

Compound 1T. A mixture of mesylate 16 (1.26 g, 3.3 mmol), thymine (462 mg, 3.7 mmol),
dried K2CO3 (1.1 g, 8.0 mmol), and NaI (600 mg, 4.0 mmol) in dry DMF (50 mL) was stirred at
90°C for 16 h. The reaction mixture was cooled and evaporated; the residue was dissolved in
ethyl acetate (50 mL). The organic layer was washed with saturated NaHCO3 solution (25 mL)
and H2O (2 x 20 mL), dried, and evaporated. The crude product was then purified by column
chromatography, affording 25% yield. 1H NMR (400 MHz, CDCl3) d 6.94 (s, 1H); 5.79 (m,
2H); 3.55 (d, J = 7.5Hz, 2H); 2.30-2.17 (m, 2H); 2.13-1.99 (m, 3H); 1.78-1.65 (m, 2H); 1.201.06 (m, 2H).

Results and Discussion
The initial monomers: design and attempted synthesis
The initial approach involved the synthesis of the monomers shown in Figure 4. These
compounds were chosen because each included an eight-membered ring containing a double
bond, a ring size that is known to be effective in ring-opening metathesis polymerization. We
16

planned to prepare monomers containing five DNA/RNA bases from a chiral allyl glycidol ether
via the same general strategy (Scheme 1).
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Figure 4. Cyclic monomers from Scheme 1
The exocyclic amino groups of guanine and adenine would be protected as Ndimethylformamidines, and the amino group of cytosine would be protected via an acetamide.
Because no protection is needed for thymine, the synthesis of 5T was attempted first. Allyl
glycidyl ether (2) was initially used as a mixture of enantiomers from a commercial source. If
this entire synthetic sequence worked, each enantiomer of 2 and subsequent compounds would
have been produced from the individual enantiomers of compound 1.
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base

O
O
5

Scheme 1
In the first step, a racemic mixture of ally glycidyl ether 2 was employed for the synthesis
of compound 3T (base = thymine); the purified product was produced in 75% yield and was
confirmed to be 3T via 1H NMR spectroscopy. In the second step, 3-bromo-2-methylpropene and
Ag2O were used to convert compound 3T to 4T, however the attempted synthesis was
unsuccessful. The desired product may have been lost or stuck to the silica used during column
chromatography. The synthesis in Scheme 1 was found to be difficult over time due to problems
with the conversion of 3T to 4T. In addition, the overall strategy would be inefficient and timeconsuming because all five bases were installed in the initial step, causing five different parallel
pathways to be necessary obtain the five equivalent cyclic monomers; therefore, the approach
shown in scheme 2 was developed to overcome this limitation, with all monomers prepared from
the same alcohol 8.

The second, more efficient approach
1. NaH, THF
2.
O

OH

O

OH

OH
O

O

39%

6

ring closing
metathesis

O

O

7
8

Scheme 2
The monomers chosen included a nine-membered ring containing two oxygens and a
double bond (Figure 5). The strategy was to first synthesize the precursor 8, a nine-membered
ring substituted with a hydroxymethyl group, via one common pathway for all monomers, then
via a subsequent reaction, the -OH group would be replaced with any of the five nucleobases,
yielding the desired cyclic monomer.
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Figure 5. Nine-membered ring monomers to be prepared from 8
Thus, to synthesize the cyclic monomers, allyl alcohol reacted with allyl glycidyl ether
(2) under basic conditions in THF, to yield the symmetrical alcohol 3 (38.5% yield). The product
structure was confirmed by 1H NMR and mass spectroscopic analysis. Compound 3, under
condition that promote ring-closing metathesis (RCM), was converted into a nine-membered ring
containing two oxygens. Trials involving a slight variation of ring-closing conditions,
summarized in Table 1, were conducted to identify the most efficient and high-yielding synthetic
method.
Table 1. Conditions for ring-closing metathesis.
Trial

Catalyst*
(amount)

Substrate
molarity

Solvent

Additive (M)

Temp.
(oC)

Time

1

G1 (10 mol %)

0.01

toluene

Ti(O-ipr)4 (0.02)

25

96 h

2

G2 (10 mol %)

0.01

toluene

Ti(O-ipr)4 (0.02)

25

48 h

3

G2 (10 mol %)

0.01

toluene

͞

25

48 h

4

G2 (10 mol %)

0.01

toluene

Ti(O-ipr)4 (0.02)

110

40 min

5

G1 (10 mol %)

0.01

toluene

͞

25

96 h

6

G2 (10 mol %)†

0.1

toluene

͞

110

40 min

7

#

G1 (10 mol %)

0.01

toluene

Ti(O-ipr)4 (0.02)

110

24 h

8

G1 (20 mol %)†

0.0012

CH2Cl2

͞

40

48 h

9

G1 (20 mol %)†

0.0005

CH2Cl2

͞

40

72 h

10

G1 (20 mol %)

0.00058

toluene

͞

110

40 min

11

G1 (20 mol %)

0.00029

toluene

Benzoquinone
(0.00058)

110

48 h

*G1 and G2 are Grubbs first- and second-generation catalysts, respectively.
#
G1 catalyst was added after 24 h reflux of substrate with Ti(O-ipr)4; mixture was heated at reflux for 40 additional
minutes.
†
After 24 hours, a second portion of catalyst, in the same amount, was added.
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After multiple trials and attempts to promote ring-closing, the desired product was
obtained but this approach was not practical due to difficulty and complexity associated with the
synthesis of a nine-membered ring, which was identified by previous studies in the chemical.
literature as one of the hardest ring sizes to synthesize.6 Therefore, the approach shown in
Scheme 3 was developed in an attempt to utilize a smaller ring that is more readily formed.
The third synthetic approach: utilizing a 7-membered ring
The monomers (Figure 6) chosen included a seven-membered ring containing a double
bond, with the initial route given in Scheme 3.

N

N

N

N

N

NH2

NH2

O

N

NH2

1G

O
R

NH

N
N

N

N

O

O

1T R = CH3
1U R = H

1C

1A

NH

Figure 6. Seven-membered ring monomers from Scheme 2

O

NaH, DMF
O

O

EtO

Br
OEt

O

EtO

OEt

Grubbs first
generation catalyst

EtO2C

100%

88%

10

9

1. NaOH, EtOH
2. decalin, heat

CO2H

62%

CO2Et

OH

1. LiAlH4
2. H3O+

base

DNA/RNA base,
PPh3, DEAD

90%
11

12

Scheme 3
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base = 9-Cl-G or T
(yields not determined),
A (27%), or U (0%)

1

This route began with the production diethyl-2,2-di-(3-butenyl)malonate from a reaction
of diethylmalonate, sodium hydride, and 4-bromo-1-butene. The successful production of diethyl2,2-di-(3-butenyl)malonate was confirmed by 1H NMR spectroscopy; the yield for this step was
88%. The diethyl-2,2-di-(3-butenyl)malonate then proceeded to undergo a ring closing metathesis
quantitatively and hydrolysis/decarboxylation to generate 4-cycloheptene-1-carboxylic acid in
62% yield. The carboxylic acid was then reduced into 5-hydroxymethylcycloheptene by LAH in a
yield of 90%. Subjecting 5-hydroxymethylcycloheptene (12) to Mitsunobu reactions employing
adenine, uracil, thymine, and a precursor to guanine to produce 1A, 1U, 1T, or a precursor to 1G
gave mixed results. The adenine, thymine, and guanine precursor analogs were successfully
produced, but the reaction with uracil did not work.
All compounds were characterized via 1H NMR spectroscopy. Due to limitations in the
amount of material that could undergo the ring-closing metathesis at one time, the strategy
Scheme 3 was modified to increase the production of 5-hydroxymethylcycloheptene, which is
the precursor to the cyclic monomers (Scheme 4).

Scheme 4
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The route in Scheme 4 employs a known synthesis of the desired 5-hydroxymethylcycloheptene (12), the precursor to the addition of the nucleobases. This preparation involved
adapting the procedure of Marquardt/Newcomb and Adkins/Hartung 7, 8 In addition, the
Mitsunobu reaction was abandoned in favor of a nucleophilic substitution to attach the
nucleobases.
Thus, we began with the synthesis of N,N-Dimethyl-1-cylclopenten-1-amine (45%) from
a reaction between dimethylamine hydrochloride and sodium hydroxide, followed by
cyclopentanone. This compound was purified via vacuum distillation. The presence of the
enamine was confirmed by 1H NMR analysis. The signal at 4.25 ppm indicated the presence of
the double bond in the cyclopentene, and the signal at 2.6 ppm with an integration of 6 showed
the presence of the methyl groups attached to a nitrogen.
N,N-dimethyl-1-cylclopenten-1-amine then reacted with acrolein, iodomethane, and a
20% aqueous solution of sodium hydroxide to produce 4-cycloheptene-1-carboxylic acid (32%).
Since acrolein is not commercially available in small quantities, it was synthesized in lab from
glycerol, potassium sulfate, and potassium bisulfate with a yield of 28%. The structures of
acrolein and 4-cycloheptene-1-carboxylic acid were confirmed via 1H NMR spectroscopy. The
aldehyde hydrogen of the acrolein corresponded to the peak at 9.5 ppm, and 4-cycloheptene-1carboxylic acid was confirmed by the presence of signals at 5.78, 2.01, 1.99, 1.98/97, and 1.72
ppm.
The 4-cycloheptene-1-carboxylic acid was then reduced with lithium aluminium hydride
to produce 5-hydroxymethylcycloheptene in 90% yield. The product was confirmed via 1H
NMR, which showed peaks at 5.78, 3.47, and 1.57 ppm, indicating the presence of the double
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bond on the ring, the methylene group coming off the ring, and the hydrogen in the alcohol
group, respectively.
Currently, we are preparing all five of the analogs of 5 via the production of the mesylate
16, which is then subjected to a nucleophilic substitution reaction to attach the nucleobases.
Thus, treatment of the alcohol 12 with mesyl chloride and an amine base in dichloromethane has
provided excellent yield of the mesylate 16.9 This compound has been successfully converted
into 1T, 1U, and 1A under a variety of conditions.10 We expect to have 1G and 1C in hand soon
using this same strategy.

Conclusion
The main goal of this research is to streamline the synthesis of antisense oligonucleotide
analogues, ultimately making the application of oligonucleotides more effective and efficient as
systemic drugs. To do so, a novel strategy of replacing the traditional ASO backbone with a
carbon ring backbone was attempted in four synthetic schemes. Each approach aimed to create a
cyclic ring that can be attached to each nucleobase, forming cyclic monomers that can be
polymerized into ASO analogs.
The first ring system attempted (Scheme 1) may have ultimately been successful; but it
was abandoned because it required each analog to be synthesized via a separate route. Therefore,
we sought an approach in which the nucleobases would be attached in the last step to a common
intermediate, (8, Scheme 2). Unfortunately, the ring-closing metathesis of 7 to form 8 proved to
be difficult (Table 1), so a completely new ring system was chosen (Figure 6). The initial
synthesis of these compounds also employed a common intermediate (12, Scheme 3), and it
successfully produced two analogs (5A and 5-Cl-G, a precursor to 5G). Although this route
employed a common intermediate and a high-yielding ring closure, the latter reaction had to be
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done at extraordinarily low concentration, requiring impractical amounts of solvent. In addition,
the Mitsunobu reaction done in the last step produced some PPh3-DEAD derived side product
that co-purified with the product in some instances. As a result, the approach in Scheme 4 was
developed. This strategy made use of an old literature preparation of 11, and employed an SN2
reaction in place of the Mitsunobu to attach the nucleobases.
Once all nucleotides have been synthesized, ring opening metathesis polymerization
reactions will be performed to synthesize full length ASO strands. Initially, we will study each
monomer’s conversion to a 20-mer of oligo-5* via a polymerization templated on a 20-mer of its
complementary oligomer in solution and on a bead (both of which can be obtained
commercially). Future work includes assessing the strength and specificity of binding of the
modified oligomers to target sequences of RNA and DNA via melting temperature curves.11 If
they do bind with specificity for the target sequences, an RNaseH resistance assay will be
conducted. Longer term goals will involve studying our modified oligonucleotides’ ability to
silence or suppress gene expression in E. coli cells that have been engineered to express the
reporter protein beta-galactosidase.
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